Plus Therapeutics, a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.
Investigators report that BrECADD, a novel therapy combination, treats classic Hodgkin lymphoma more effectively and with fewer side effects than BEACOPP, the standard intensive therapy regimen. BrECADD includes… read more.
ASCO: In resectable stage III melanoma, treatment with the immunotherapies ipilimumab and nivolumab before lymph nodes are surgically removed is more effective than treatment with nivolumab after the… read more.
Researchers report that adding belantamab mafodotin to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma is more effective at slowing disease progression or death… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
